Previous Close | 13.30 |
Open | 10.20 |
Bid | 8.00 |
Ask | 12.50 |
Strike | 97.50 |
Expire Date | 2024-06-21 |
Day's Range | 10.00 - 10.20 |
Contract Range | N/A |
Volume | |
Open Interest | 69 |
On May 30, 2024, Gail Marcus, Director at Natera Inc (NASDAQ:NTRA), executed a sale of 2,000 shares of the company at a price of $110.17 per share.
On May 28, 2024, Rowan Chapman, Director at Natera Inc (NASDAQ:NTRA), sold 4,856 shares of the company.
AUSTIN, Texas, May 30, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1–5, 2024.